362 related articles for article (PubMed ID: 34729944)
1. Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates.
Pan X; Yamazaki S; Neuhoff S; Zhang M; Pilla Reddy V
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1485-1496. PubMed ID: 34729944
[TBL] [Abstract][Full Text] [Related]
2. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
[TBL] [Abstract][Full Text] [Related]
3. Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney.
Asaumi R; Nunoya KI; Yamaura Y; Taskar KS; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):919-933. PubMed ID: 35570332
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
5. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
Otsuka Y; Choules MP; Bonate PL; Komatsu K
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of drug-drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling.
Ji T; Chen X; Yeleswaram S
CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):894-905. PubMed ID: 35506332
[TBL] [Abstract][Full Text] [Related]
7. Physiologically based pharmacokinetic modelling to predict drug-drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors.
Kollipara S; Ahmed T; Praveen S
Xenobiotica; 2023 May; 53(5):366-381. PubMed ID: 37609899
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach.
Hanley MJ; Yeo KR; Tugnait M; Iwasaki S; Narasimhan N; Zhang P; Venkatakrishnan K; Gupta N
CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):624-637. PubMed ID: 38288787
[TBL] [Abstract][Full Text] [Related]
9. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
Baneyx G; Parrott N; Meille C; Iliadis A; Lavé T
Eur J Pharm Sci; 2014 Jun; 56():1-15. PubMed ID: 24530864
[TBL] [Abstract][Full Text] [Related]
10. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
Narayanan R; Hoffmann M; Kumar G; Surapaneni S
Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
[TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
[TBL] [Abstract][Full Text] [Related]
12. Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction.
Kapetas AJ; Sorich MJ; Rodrigues AD; Rowland A
AAPS J; 2019 Jun; 21(5):78. PubMed ID: 31218462
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
14. Assessment of cytochrome P450 3A4-mediated drug-drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model.
Jing J; Chen Y; Musib L; Jin JY; Cheung KWK; Yoshida K; Sane R
Cancer Chemother Pharmacol; 2022 May; 89(5):707-720. PubMed ID: 35428895
[TBL] [Abstract][Full Text] [Related]
15. Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug-Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors.
Chen G; Sun K; Michon I; Barter Z; Neuhoff S; Ghosh L; Ilic K; Song IH
J Clin Pharmacol; 2024 May; 64(5):590-600. PubMed ID: 38009271
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
Cicali B; Lingineni K; Cristofoletti R; Wendl T; Hoechel J; Wiesinger H; Chaturvedula A; Vozmediano V; Schmidt S
CPT Pharmacometrics Syst Pharmacol; 2021 Jan; 10(1):48-58. PubMed ID: 33217171
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms.
Srinivas NR
Drugs R D; 2016 Jun; 16(2):141-8. PubMed ID: 27098526
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
[TBL] [Abstract][Full Text] [Related]
19. Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.
Yamazaki S; Loi CM; Kimoto E; Costales C; Varma MV
Drug Metab Dispos; 2018 Aug; 46(8):1200-1211. PubMed ID: 29739809
[TBL] [Abstract][Full Text] [Related]
20. Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
Posada MM; Morse BL; Turner PK; Kulanthaivel P; Hall SD; Dickinson GL
J Clin Pharmacol; 2020 Jul; 60(7):915-930. PubMed ID: 32080863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
